Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8675251 | Progress in Cardiovascular Diseases | 2018 | 34 Pages |
Abstract
Determining the optimal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention is a complex decision. Randomized controlled trials have shown that while shorter durations of DAPT may lower the risk of bleeding, longer durations of DAPT can reduce the risk of late stent thrombosis and ischemia-related events. In this review article, we will discuss the current guidelines, review contemporary trial data that have evaluated short and extended durations of DAPT, and address common clinical questions. Ultimately, the determination of the optimal duration of DAPT is an individualized decision that requires clinicians to assess each patient's risk for bleeding and recurrent ischemic events.
Keywords
E-ZESACCMACCEEESBMSDAPTACSAHADESDrug-eluting stentseverolimus-eluting stentsbare metal stentsEuropean Society of CardiologyAmerican Heart Associationcoronary artery diseasechronic kidney diseaseESCdual antiplatelet therapyGastrointestinalacute coronary syndromesbody mass indexBMICADconfidence intervalcardiovascularCKDhazard ratioAmerican College of Cardiology
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Mahesh K. Vidula, Eric A. Secemsky, Robert W. Yeh,